Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Up 7.19%
As of Friday, August 21, Tango Therapeutics, Inc.’s TNGX share price has surged by 7.19%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Which Is a Better Investment, Tango Therapeutics, Inc. or Xencor, Inc. Stock?
Learn more about whether Tango Therapeutics, Inc. or Xencor, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Which Is a Better Investment, CRISPR Therapeutics AG or Tango Therapeutics, Inc. Stock?
Learn more about whether CRISPR Therapeutics AG or Tango Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Down 5.97%
As of Friday, August 07, Tango Therapeutics, Inc.’s TNGX share price has dipped by 5.97%, which has investors questioning if this is right time to buy.Michael Rose
Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Up 5.68%
As of Tuesday, August 04, Tango Therapeutics, Inc.’s TNGX share price has surged by 5.68%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,026.4 | $292.6 | 63% |
|
| Shares Out (Mil) | 149.9 | 54.4 | 71% |
|
| Institutional Ownership | 98.9% | 93.2% | 83% |
|
| Float (Mil) | 120.3 | 40.2 | 65% |
|
| Beta | 1.15 | 0.94 | 69% |
|
| Avg Daily Volume (000s) | 2,174 | 544 | 83% |
|
| Price Change (52-week) |
253.8% | 59.7% | 98% |
|
| Growth | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 52.0% | 13.6% | 96% |
|
| Net Income (5yr) | (14.3%) | (10.1%) | 26% |
|
| EPS (5yr) | 11.7% | 16.0% | 50 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 16.8% | (15.6%) | 76% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 13 | 13 | 13 | |
| Current EPS | ($0.346) | ($1.380) | ($1.628) | |
| Month Ago EPS | ($0.330) | ($1.294) | ($1.520) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.344) | ($1.347) | ($1.583) | |
| Year/Year Chg | (6.2%) | 57.7% | 109.0% | |
| Financials | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $54 | $37 | 21% |
|
| Net Income (TTM) (Mil) | ($124) | ($43) | 10% |
|
| EPS (TTM) | ($0.915) | ($1.400) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($144) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $306 | $2 | 87% |
|
| Long-Term Debt (Q1) (Mil) | $29 | $4 | 35% |
|
| Enterprise Value (Q1) (Mil) | $3,459 | $164 | 57% |
|
| Valuation | TNGX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.93 | 2.83 | 72% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (148.4%) | 64.2% | 1% |
|
| Net Margin | (229.9%) | (75.9%) | 4% |
|
| ROA | (18.9%) | (47.5%) | 21% |
|
| ROE | (21.3%) | (55.0%) | 23% |
|
| Liabilities to Assets | 4.6% | 29.6% | 2% |
|
| F-Score | 4 | 3 | 33% |
|
Tango Therapeutics, Inc. did not pass any screens on 8/21/2026.
